Rosiglitazone ameliorates cisplatin-induced renal injury in mice

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2096-2105

  Lee, Sik ^a   Kim, Won ^a   Moon, Sang Ok ^a   Sung, Mi Jeong ^a   Kim, Duk Hoon ^a   Kang, Kyung Pyo ^a   Jang, Yong Bum ^a   Lee, Jung Eun ^a   Jang, Kyu Yun ^a   Park, Sung Kwang ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Cisplatin; Nuclear factor B; Rosiglitazone; Tumour necrosis factor

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; AQUAPORIN 2; CIGLITAZONE; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY INJURY; MACROPHAGE ACTIVATION; MALE; MOUSE; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION;

ANILIDES; ANIMALS; APOPTOSIS; C-PEPTIDE; CELL LINE; CHROMANS; CISPLATIN; DRUG EVALUATION, PRECLINICAL; GLIOMA; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TUBULES, PROXIMAL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; PPAR GAMMA; PROSTAGLANDIN D2; PROTEIN TRANSPORT; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748056444     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl194     Document Type: Article

References (20)

1. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8: 368-379
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464
3. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842
4. Alberts B. Molecular Biology of the Cell. 2002: Garland Science, New York: 2002; 898
5. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int 2004; 65: 490-498
6. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr Opin Biotechnol 1999; 6: 590-595
7. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rey 1999; 20: 649-688
8. Cuzzocrea S, Pisano B, Dugo L et al. Rosiglitazone, a ligand of the peroxisome proliferators-activated receptor-γ, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79-93
9. Jiang C, Ting A, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86
10. 2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol Cell Biol 2002; 80: 531-536
11. Chung SW, Kang BY, Kim SH et al. Oxidized low density lipoprotein inhibits interleukin 12 production in lipopolysaccharide-activated mouse macrophages via direct interaction between PPARγ and NF-κB. J Biol Chem 2000; 276: 32681-32687
12. Tramonti G, Romtti N, Norpoth M, Chieli E. P-glycoprotein in HK-2 proximal tubule cell line. Ren Fail 2001; 23: 331-337
13. Ahn SY, Cho CH, Park KG et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 2004; 164: 1663-1672
14. Kim SW, Lee JU, Nah MY et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001; 12: 875-882
15. Nakajima A, Wada K, Miki H et al. Endogenous PPARγ mediates anti-inflammatory activity in murine ishemia-reperfusion injury. Gastroenterology 2001; 120: 460-469
16. Chaney SG, Campbell SL, Temple B et al. Protein interactions with platinum-DNA adduct: From structure to function. J Inorg Biochem 2004; 98: 1551-1559
17. Hannemann J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicol 1988; 51: 119-132
18. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005; 67: 458-466
19. Lee S, Kim W, Kang KP et al. Agonist of peroxisome-proliferator activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057-1065
20. Safirstein R, Winston J, Moel D et al. Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 1987; 10: 325-346